Successful formation of electronic interfaces between living cells and electronic components requires both good cell viability and performance level. This paper presents a technology for the formation of nanostructured arrays of multi-walled carbon nanotubes (MWCNT) in biopolymer (albumin) layer for higher biocompatibility. The layer of liquid albumin dispersion was sprayed on synthesized MWCNT arrays by deposition system. These nanostructures were engineered using the nanosecond pulsed laser radiation mapping in the near-IR spectral range (λ = 1064 nm). It was determined that the energy density of 0.015 J/cm2 provided a sufficient structuring of MWCNT. The structuring effect occurred during the formation of C–C bonds simultaneously with the formation of a cellular structure of nanotubes in the albumin matrix. It led to a decrease in the nanotube defectiveness, which was observed during the Raman spectroscopy. In addition, laser structuring led to a more than twofold increase in the electrical conductivity of MWCNT arrays with albumin (215.8 ± 10 S/m). Successful electric stimulation of cells on the interfaces with the system based on a culture plate was performed, resulting in the enhanced cell proliferation. Overall, the MWCNT laser-structured arrays with biopolymers might be a promising material for extended biomedical applications.

Background: Mantle cell lymphoma (MCL) is a B cell malignancy accounting for 3-10% of all Non-Hodgkin Lymphomas and arises mainly in older adults with a male predominance (McKey et al). Historically, median survival was 4-5 years (Herrmann et al, 2009) however this is now in the order of 8-12 years in younger fitter patients who are able to tolerate intensive therapies (Eskelund et al, 2016). The current standard treatment is chemoimmunotherapy with or without autologous stem cell transplantation (ASCT). Although intensive therapy can achieve durable responses most patients eventually succumb to their disease. Novel therapeutic agents have shown efficacy in relapsed/refractory disease and are now being tested as frontline treatment (Sharma et al, 2018). Aims: We report a single centre experience of MCL and its treatment. Methods: Retrospective data was collected on all patients diagnosed with MCL at Ipswich Hospital NHS Trust over a nine year period between January 2010 and January 2019. Results: Forty-two patients were included in the analysis. Median age was 68yrs with a male to female ratio of 5:1. Eastern Co-operative Oncology Group (ECOG) performance status ranged from 0-1 in 66%, ≥2 in 14% and 19% had no status documented. Twenty-four patients (57%) received a non-intensive chemoimmunotherapy regimen; rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab-bendamustine (BR) as first line treatment with twenty of these patients receiving rituximab maintenance. Thirteen patients (31%) were fit enough to receive an intensive chemoimmunotherapy regimen with all but one consolidated with an ASCT. Of those transplanted five went on to receive rituximab maintenance. The remaining 12% of patients received either R-Chlorambucil, palliative radiotherapy, FCR or supportive care. The median Kaplan-Meier overall survival (OS) for all patients had not been reached. Median progression free survival (PFS) was 48 months. Comparing first line therapies, the median OS for those that received RCHOP/BR was 60 months with a median PFS of 35 months vs. not reached for both OS and PFS with intensive chemoimmunotherapy followed by ASCT. Eighteen patients had relapsed during the nine year period. There was no standard second line treatment. Eight patients received further chemoimmunotherapy including BR, R-cytarabine and FCR, one PEP-C, three ibrutinib, four palliative radiotherapy and two received supportive care only. After first relapse median PFS was 6 months and median OS was only 10 months. Nine patients received a third line treatment, of which 3 received ibrutinib and one venetoclax and the median OS was 9 months. The six relapsed/refractory patients that received Ibrutinib at either first or second relapse had a median OS of 8 months vs. 12 months in those that received other forms of therapy. Summary/Conclusion: As expected the best outcomes were with high intensity regimens consolidated by ASCT. Our data period was not long enough to show the continuous pattern of relapse despite durab...

4419 Background ALK-Positive Anaplastic Large Cell Lymphoma (ALCL ALK+) represent 5–15% of all non-Hodgkin in children and 5% in adults and characterized by the specific chromosome translocations, which lead to the break of gene ALK. Currently describe 9 translocations. All of them have no prognostic significance. Purpose We present a case of ALCL ALK+ with a new chromosomal rearrangement involving locus gene 2p23 and poor response to therapy. Case presentation. A 24-year old woman presented to our clinic with a month history of right axillar tumor 20×9 sm. Full examination reveals B-symptoms, the involvement of the mammary gland, generalized lymphadenopathy and splenomegaly. The diagnosis ALCL ALK+ was made on the base of CD30 and ALK expression and ALK gene rearrangement. Cytogenetic analysis showed a normal karyotype including a new translocation t(2;8)(p23;q22). In our centre we provided the pilot study of the efficacy of the protocol NHL BFM-90 in adult ALCL ALK+. Overall five-year survival rate is 90%±6% (n=25). The patient was treated according to the program, branch K3 (6 cycles AA-BB-C-AA-BB-C, the dose of methotrexate 5 g/m2). The remission was achieved after 4 cycle. CNS prophylaxis was made in the first cycle of the chemotherapy (intrathecal administration of methotrexate 15 mg, cytarabine 30 mg and dexamethasone 4 mg). A weak after the last cycle of the chemotherapy the patient complained of intensive headache. Neuroleukemia was diagnosed (100 cells in μl large anaplastic cells expressed CD30, ALK, and have ALK rearrangement). Full examination revealed no other tumor lesions. The patient was treated with 10 intrathecal administration of methotrexate, ara-C and dexamethasone. The normalization of the cerebrospinal fluid was after the 7th lumbar puncture. Currently the patient is treated following chemotherapy program for relapsed lymphomas. Conclusions we presented a case of primary progressive course of ALCL ALK+ with a new chromosomal rearrangement t(2;8)(p23;q22). To the best of our knowledge and after literature search this appears to be a new cytogenetic abnormality in ALCL ALK+. It was the first case of progression of ALCL ALK+ on the intensive program NHL BFM-90 in adults in our experience. So we propose that this translocation may be associated with unfavorable prognosis. Further trials and study of pathogenesis of t(2;8)(p23;q22) to confirm our observation. Disclosures: No relevant conflicts of interest to declare.

No abstract

Background. The management of aggressive lymphomas in pregnancy depends on the time of diagnosis and immu-nomorphological variant of tumor. The rarity of aggressive lymphomas in pregnant women, the absence of consistent approaches to the treatment of such patients, the lack of data on physical growth of children as well as the incidence of newborns’ congenital and acquired pathology make this subject of vital importance. Aim. To analyze the treatment results in patients with newly diagnosed aggressive lymphoma at different stages of pregnancy. Materials & Methods. From 1993 to 2020 at the National Research Center for Hematology 74 pregnant women with lymphomas were treated. Aggressive tumors were detected in 17 (23 %) of them: primary mediastinal (thymic) large B-cell lymphoma (п = 14), anaplastic large-cell lymphoma ALK+ (п = 1), high-grade B-cell lymphoma, unspecified (п = 1), and diffuse large B-cell lymphoma (п = 1). The median age of patients was 30 years (range 21-37 years). The median pregnancy stage on the diagnosis of aggressive lymphoma was 21 weeks (range 11-32 weeks). Results. In 1 case on the diagnosis of aggressive lymphoma at 11 weeks gestation dexamethasone 8 mg daily was administered up to the second trimester of pregnancy, afterwards the patient received polychemotherapy. On the diagnosis of aggressive lymphoma in the second (п = 13) and third (п = 2) trimesters of pregnancy the patients received polychemotherapy followed by delivery. In the third trimester of pregnancy delivery was performed with subsequent polychemotherapy in 1 patient. There were born 18 babies (1 pregnancy was multifetal): 8 girls and 10 boys. Conclusion. As a result of the chosen tactics and the work of interdisciplinary team of doctors all patients, who completed the treatment, are followed-up in complete remission. All born babies, despite chemotherapy and perinatal complications, are alive and develop without abnormalities.